此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Root Extract Ashwagandha (KSM-66) on Perception of Recovery and Muscle Strength in Adolescents Aged 11 to 19 Engaged in Grassroots Football

2026年11月12日 更新者:Alex Levington、Sports Performance and Applied Research in Trials and Analysis

Effects of KSM-66 Ashwagandha (Withania Somnifera) Root Extract Supplementation on Perception of Recovery and Muscle Strength in Adolescents in Grassroots Football: A Randomised, Double-Blind, Placebo-Controlled Trial

This study will test whether six weeks of ashwagandha (KSM-66 root extract), helps teenage footballers recover and improve strength. Very little research has looked at young people aged 11 to 19, despite increased usage in this cohort.

About 50 to 60 male and female players from grassroots clubs in Sussex, Surrey and Greater London will be randomly assigned to take a daily capsule of either 450 mg ashwagandha or a placebo in an unblinded fashion. Before and after the six weeks, players will do tests at their usual training site: saliva samples to measure the cortisol, grip strength, a 1 km time trial, and short questionnaires on recovery, sleep, stress and soreness.

The results will show whether ashwagandha changes stress, strength, performance and perceived recovery over six weeks.

研究概览

详细说明

This randomised, double-blind, placebo-controlled trial will test whether KSM-66 ashwagandha (Withania somnifera) root extract alters physiological stress, neuromuscular performance and perceived recovery in adolescent footballers. In adults, standardised root extract has been associated with improved strength, recovery, sleep and reduced cortisol. In children, the only placebo-controlled trial of root extract (ages 6 to 12) examined cognition and sleep. No trial has studied adolescents, whose growth, maturation and training load may alter responses, so adult findings cannot be assumed to apply.

An independent collaborator outside the research team will generate the allocation (block size four, stratified by sex and age band, 11 to 15 and 16 to 19) and label bottles with participant codes only. Participants, caregivers and investigators will remain blind until the dataset is locked, and blinding success will be assessed at follow-up. Players aged 11 to 15 take part with parental consent and their own assent, and players aged 16 to 19 consent for themselves. A study medical official will screen medical eligibility. Caregivers or participants will be contacted weekly regarding adverse events, and any suspected supplement-related event will lead to discontinuation and medical review within 24 hours.

Data will be analysed by linear mixed methods. Two investigators will analyse the coded data independently and blind to allocation. Results will be interpreted as short-term responses and will not establish long-term safety or efficacy.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

11年 至 19年 (孩子、成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Aged 11 to 19 years on the day of baseline testing
  • Male or female player registered with a participating grassroots football club or community football programme, taking part in organised football training at least once a week (any playing ability)
  • Able to attend both testing sessions and able to swallow a capsule
  • Valid written consent: parent/caregiver consent and player assent (ages 11 to 17), or the player's own consent (ages 18 to 19)

Exclusion Criteria:

  • Diagnosed liver, kidney or thyroid condition
  • Autoimmune condition (e.g. type 1 diabetes, lupus, rheumatoid or juvenile idiopathic arthritis, inflammatory bowel disease)
  • Diabetes or another condition affecting blood sugar; high or low blood pressure requiring treatment
  • Regularly taking prescribed medication
  • Known allergy or intolerance to ashwagandha, nightshade family plants, corn (maize) or the capsule shell
  • Pregnant, possibly pregnant or breastfeeding
  • Stomach ulcer; heart condition; chest pain, fainting or seizures during exercise; or medical advice not to do hard exercise
  • Current illness or injury that prevents maximal effort
  • Surgery planned during the study or within 2 weeks after it, or hospital admission in the last 3 months
  • Currently taking, or taken in the past 4 weeks, ashwagandha in any form, including combination products
  • Unwilling to avoid starting any new supplement during the six weeks
  • Taking part in another research study involving a supplement or medicine in the past 3 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Root extract Ashwagandha

450mg of KSM-66 Ashwagandha

One 450 mg capsule of KSM-66 ashwagandha, taken once daily with a meal for six weeks (42 days). KSM-66 is a full-spectrum extract made from root only, with no leaf, standardised to 5% withanolides (HPLC verified), and supplied with a certificate of analysis for each batch. Capsules are supplied in labelled bottles of 42 and are identical in appearance to the placebo.

其他名称:
  • KSM-66
安慰剂比较:Placebo

450mg corn starch

One 450 mg capsule of corn starch, taken once daily with a meal for six weeks (42 days). The capsule shell, appearance, bottle and labelling are identical to the active capsule.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Salivary cortisol
大体时间:Baseline (week 0) and after six weeks of supplementation

Saliva collected with Salivette tubes after an evening training session and analysed by an external laboratory. Reported as the change from baseline to follow-up.

Baseline (week 0) and after six weeks of supplementation

次要结果测量

结果测量
措施说明
大体时间
Salivary alpha-amylase
大体时间:Baseline (week 0) and after six weeks of supplementation

Measured from the same saliva samples as cortisol.

Baseline (week 0) and after six weeks of supplementation
Handgrip Strength
大体时间:Baseline (week 0) and after six weeks of supplementation

Maximal handgrip strength measured with a CAMRY handgrip dynamometer.

Baseline (week 0) and after six weeks of supplementation
Number of participants with adverse events
大体时间:Baseline (week 0) and after six weeks of supplementation

Any adverse events reported in the duration of the clinical trial

Baseline (week 0) and after six weeks of supplementation
Change in perceived recovery, measured by the Hooper Index
大体时间:Baseline (week 0) and after six weeks of supplementation

Self-reported fatigue, stress, sleep quality and muscle soreness on the Hooper Index questionnaire. Individual items are scored 1 (very, very good) to 10 (very, very bad) and the total score is 4 to 40, higher scores indicating poorer recovery.

Baseline (week 0) and after six weeks of supplementation
Change in 1 km time-trial performance
大体时间:Baseline (week 0) and after six weeks of supplementation

Time taken to complete a 1 km run, as a measure of aerobic fitness and high-intensity running capacity.

Baseline (week 0) and after six weeks of supplementation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2026年12月20日

研究完成 (估计的)

2026年12月20日

研究注册日期

首次提交

2026年10月14日

首先提交符合 QC 标准的

2026年10月14日

首次发布 (实际的)

2026年10月22日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • ASH-ADOL-001

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared. Participants will be minors recruited from a small number of local football clubs, so a dataset of this size (about 50 to 60 players) combined with age, sex and test results could allow re-identification even after coding. Consent and assent were obtained for use of the data within this study only, and the participant code key and contact details will be permanently deleted on 31 May 2027. The fully anonymised dataset will be held securely by the research team and used only for the analyses and publications described in the ethics-approved protocol. Summary results will be reported in the results section of this record and in peer-reviewed publication, with participating clubs not named.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅